Summary
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DH Dinan Hu R Squared Ltd | 11,276 | $20,213.65 | $10,732.5 | -$9,481.15 | -46.9% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 46,800 | $21,425 | $44,544.24 | $23,119.24 | 107.91% |
| RO Regan O'Neill Burkehill Global Management LP | 500,000 | $795,000 | $458,950 | -$336,050 | -42.27% |
| JS Jeffrey Sjovall Phraction Management LLC | 41,000 | $18,778 | $37,519.1 | $18,741.1 | 99.8% |
| OM Olga Maltseva Catalio Capital Management LP | 5.49M | $9M | $4.72M | -$4.28M | -47.55% |
Fractyl Health Inc. (GUTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fractyl Health Inc. ever had a stock split?
Fractyl Health Inc. Profile
| Biotechnology Industry | Healthcare Sector | Harith Rajagopalan CEO | NASDAQ (NMS) Exchange | 35168W103 CUSIP |
| US Country | 102 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Fractyl Health, Inc. is a metabolic therapeutics company committed to developing innovative treatments for type 2 diabetes (T2D) and obesity. Originally founded as Fractyl Laboratories Inc., the company underwent a name change to Fractyl Health, Inc. on June 09, 2021. Since its incorporation in 2010, Fractyl Health has been at the forefront of addressing the underlying causes of these metabolic disorders. Its headquarters are located in Burlington, Massachusetts, signifying its strong presence in the hub of health and biotech innovation.
Products and Services
- Revita DMR System (Revita)
- Rejuva
Fractyl Health, Inc. has developed the Revita DMR System, an advanced outpatient procedural therapy primarily aimed at modifying duodenal dysfunction. This condition arises as a pathological consequence of consuming a high fat and high sugar diet, leading to the initiation of T2D and obesity in individuals. Revita represents a significant stride in durable treatment methods, focusing on the root cause rather than simply managing symptoms of these widespread metabolic disorders.
Expanding its suite of groundbreaking metabolic treatments, Fractyl Health, Inc. is also pioneering Rejuva, a novel gene therapy platform. Utilizing adeno-associated virus vectors, Rejuva targets the pancreatic islet cells to durably alter the function of metabolic hormones. This innovative approach is designed to achieve long-term remission of T2D and obesity, potentially revolutionizing the way these conditions are treated by directly addressing their metabolic underpinnings.
